SOMC Cancer Center & Infusion

Ph: (740) 356-7490 Fx: (740) 356-7488

Vedolizumb (Entyvio) Order Form

PATIENT & PRESCRIBER INFORMATION								
Patient Name:		DOB:		Phone	e: (H)		(C)	
-t.: W	t.: 🗆 lbs. 🗆	kg. Allergies:						
Prescriber Name/Tit	:le:		Address:					
Phone:	Fax:		Presc	riber NP	PI #:			
	cent H&P, clinical not any past tried and/o		•		-		• • • •	clinical
	DIA	GNOSIS, CLINICA	AL INFORMA	TION, 8	RESCRIP	TION		
	follow manufacture	recommendations.						
oxtimes In the event of an	adverse reaction, lin	e maintenance/flush	ies, or O2 are re	quired, 1	the SOMC AIC	established	protocols will be uti	lized.
☑ 0.9% NaCl 250 ml	primary at KVO durir	g infusion and for li	ne flushing.					
☑ Monitor for anv a	dverse events post a	dministration for at I	east 30 minutes	s or until	l clinically stab	le.		
•	edications: (Check al				-		ration	
	(Tylenol) 650 mg by		ummstered St	, ,,,,,,,	es prior to cae	iii aaiiiiiiiist	i diloii.	
•	ng Diphenhydramine		r □ IV v 1 doso					
•	•							
	lone (Solumedrol) _							
☐ Other (Please S	pecify) ⁻							
			— AND —					
Diagnosis (Check all								
☐ Moderate	to Severe Active	☐ Moderate to	Severe Active					
Ulcerative	Colitis	Crohn's Disea	se					
Dose:								
☐ Vendolizuma	ab (Entyvio) 300 mg I	V Day 0, repeat dos	e at week 2 an	d week 6	6 and then eve	ery 8 weeks	for up to tir	nes
☐ Vendolizuma	ab (Entyvio) 300 mg I	V every 8 weeks x 1	year					
☐ Vendolizuma	ab (Entyvio) 300 mg I	V every we	eeks x 1 year					
		, <u></u> _	,					
Additional order(s)								
Lab order(s)								
□ СВС	☐ at each dose	or 🗆 every	_					
☐ CBC w/ Diff		or 🗆 every						
□ смр		or 🗆 every						
☐ Other –			-					
		PROVIDER:	DATE: TI	ME:	SIGNATURE:			



Created: 11/13/23	P & T Comm.			
Reviewed & Approved	11/14/23			
Next Review Date	11/14/25			
Version	V11132023.0			